Trial Profile
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2023
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms TICA KOREA
- 25 Sep 2023 Results analyzing Age- and Sex-Specific Disparities in Outcomes After Ticagrelor Versus Clopidogrel in East Asian Patients published in the American Journal of Cardiology
- 25 Sep 2019 Results published in the Circulation.
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.